The baseline insulin data given in Table 1 for the placebo group were incorrectly reported as 51 ± 10 pmol/l instead of 48 ± 10 pmol/l. This mistake also impacts on data reported in Table 4 . The authors also note an error in the reported change in noradrenaline levels, from pre-to post-pioglitazone treatment (Table 4 ). The relevant rows from Tables 1 and 4 are reproduced here, with corrected data shown in bold. These corrections do not change the statistical significance of any comparison. Data are means ± SEM
The online version of the original article can be found at https://doi.org/10. 1007/s00125-017-4479-9 Insulin (pmol/l) 48 ± 10 43 ± 3 −4.2 ± 8.0 36 ± 4 38 ± 6 1.3 ± 3.9
Data are means ± SEM Change represents the difference between pre-and post-intervention for each group (Post−Pre)
